KW 2449

01/01/2023 - "KW2449 ameliorates collagen-induced arthritis by inhibiting RIPK1-dependent necroptosis."
01/01/2023 - "Collagen-induced arthritis (CIA) rats were treated with KW2449 by gavage for 28 days. "

05/15/2011 - "Combining KW-2449 with HDACIs warrants attention in IM-resistant Bcr/Abl(+) leukemias."
08/20/2009 - "These results indicate KW-2449 has potent growth inhibitory activity against various types of leukemia by several mechanisms of action. "
08/20/2009 - "KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation."
08/20/2009 - "Our studies indicate KW-2449 has significant activity and warrants clinical study in leukemia patients with FLT3 mutations as well as imatinib-resistant mutations."
08/20/2009 - "KW-2449 showed the potent growth inhibitory effects on leukemia cells with FLT3 mutations by inhibition of the FLT3 kinase, resulting in the down-regulation of phosphorylated-FLT3/STAT5, G(1) arrest, and apoptosis. "

08/20/2009 - "Oral administration of KW-2449 showed dose-dependent and significant tumor growth inhibition in FLT3-mutated xenograft model with minimum bone marrow suppression. "
01/01/2021 - "In this study, we identified that the multitargeted kinase inhibitor KW-2449 inhibited cisplatin-induced necroptosis, while potentiated cisplatin-induced apoptosis in cancer cells. "

01/01/2021 - "Anti-Inflammatory Effect of KW-2449 on Autoimmune Encephalomyelitis: An Experimental Study on Mice."

05/15/2011 - "Bcr/Abl(+) chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) cells, including those resistant to IM (T315I, E255K), were exposed to KW-2449 in the presence or absence of vorinostat or SNDX-275, after which apoptosis and effects on signaling pathways were examined. "